Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI.
Jacobian determinant
Longitudinal voxel-wise analysis
MRI
Machine learning
Preclinical AD signature
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
17 08 2019
17 08 2019
Historique:
received:
20
02
2019
accepted:
23
07
2019
entrez:
19
8
2019
pubmed:
20
8
2019
medline:
16
7
2020
Statut:
epublish
Résumé
Magnetic resonance imaging (MRI) has unveiled specific alterations at different stages of Alzheimer's disease (AD) pathophysiologic continuum constituting what has been established as "AD signature". To what extent MRI can detect amyloid-related cerebral changes from structural MRI in cognitively unimpaired individuals is still an area open for exploration. Longitudinal 3D-T1 MRI scans were acquired from a subset of the ADNI cohort comprising 403 subjects: 79 controls (Ctrls), 50 preclinical AD (PreAD), and 274 MCI and dementia due to AD (MCI/AD). Amyloid CSF was used as gold-standard measure with established cutoffs (< 192 pg/mL) to establish diagnostic categories. Cognitively unimpaired individuals were defined as Ctrls if were amyloid negative and PreAD otherwise. The MCI/AD group was amyloid positive. Only subjects with the same diagnostic category at baseline and follow-up visits were considered for the study. Longitudinal morphometric analysis was performed using SPM12 to calculate Jacobian determinant maps. Statistical analysis was carried out on these Jacobian maps to identify structural changes that were significantly different between diagnostic categories. A machine learning classifier was applied on Jacobian determinant maps to predict the presence of abnormal amyloid levels in cognitively unimpaired individuals. The performance of this classifier was evaluated using receiver operating characteristic curve analysis and as a function of the follow-up time between MRI scans. We applied a cost function to assess the benefit of using this classifier in the triaging of individuals in a clinical trial-recruitment setting. The optimal follow-up time for classification of Ctrls vs PreAD was Δt > 2.5 years, and hence, only subjects within this temporal span are used for evaluation (15 Ctrls, 10 PreAD). The longitudinal voxel-based classifier achieved an AUC = 0.87 (95%CI 0.72-0.97). The brain regions that showed the highest discriminative power to detect amyloid abnormalities were the medial, inferior, and lateral temporal lobes; precuneus; caudate heads; basal forebrain; and lateral ventricles. Our work supports that machine learning applied to longitudinal brain volumetric changes can be used to predict, with high precision, the presence of amyloid abnormalities in cognitively unimpaired subjects. Used as a triaging method to identify a fixed number of amyloid-positive individuals, this longitudinal voxel-wise classifier is expected to avoid 55% of unnecessary CSF and/or PET scans and reduce economic cost by 40%.
Sections du résumé
BACKGROUND
Magnetic resonance imaging (MRI) has unveiled specific alterations at different stages of Alzheimer's disease (AD) pathophysiologic continuum constituting what has been established as "AD signature". To what extent MRI can detect amyloid-related cerebral changes from structural MRI in cognitively unimpaired individuals is still an area open for exploration.
METHOD
Longitudinal 3D-T1 MRI scans were acquired from a subset of the ADNI cohort comprising 403 subjects: 79 controls (Ctrls), 50 preclinical AD (PreAD), and 274 MCI and dementia due to AD (MCI/AD). Amyloid CSF was used as gold-standard measure with established cutoffs (< 192 pg/mL) to establish diagnostic categories. Cognitively unimpaired individuals were defined as Ctrls if were amyloid negative and PreAD otherwise. The MCI/AD group was amyloid positive. Only subjects with the same diagnostic category at baseline and follow-up visits were considered for the study. Longitudinal morphometric analysis was performed using SPM12 to calculate Jacobian determinant maps. Statistical analysis was carried out on these Jacobian maps to identify structural changes that were significantly different between diagnostic categories. A machine learning classifier was applied on Jacobian determinant maps to predict the presence of abnormal amyloid levels in cognitively unimpaired individuals. The performance of this classifier was evaluated using receiver operating characteristic curve analysis and as a function of the follow-up time between MRI scans. We applied a cost function to assess the benefit of using this classifier in the triaging of individuals in a clinical trial-recruitment setting.
RESULTS
The optimal follow-up time for classification of Ctrls vs PreAD was Δt > 2.5 years, and hence, only subjects within this temporal span are used for evaluation (15 Ctrls, 10 PreAD). The longitudinal voxel-based classifier achieved an AUC = 0.87 (95%CI 0.72-0.97). The brain regions that showed the highest discriminative power to detect amyloid abnormalities were the medial, inferior, and lateral temporal lobes; precuneus; caudate heads; basal forebrain; and lateral ventricles.
CONCLUSIONS
Our work supports that machine learning applied to longitudinal brain volumetric changes can be used to predict, with high precision, the presence of amyloid abnormalities in cognitively unimpaired subjects. Used as a triaging method to identify a fixed number of amyloid-positive individuals, this longitudinal voxel-wise classifier is expected to avoid 55% of unnecessary CSF and/or PET scans and reduce economic cost by 40%.
Identifiants
pubmed: 31421683
doi: 10.1186/s13195-019-0526-8
pii: 10.1186/s13195-019-0526-8
pmc: PMC6698344
doi:
Substances chimiques
Amyloid beta-Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
72Subventions
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España
ID : MALEGRA TEC2016-75976-R
Pays : International
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España
ID : RYC-2013-13054
Pays : International
Organisme : European Regional Development Fund
ID : MALEGRA TEC2016-75976-R
Pays : International
Organisme : Ministerio de Educación, CUltura y Deporte
ID : FPU
Pays : International
Références
Neuroimage. 2017 Jan 15;145(Pt B):166-179
pubmed: 27989847
Neurobiol Aging. 2010 Aug;31(8):1340-54
pubmed: 20570401
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
PLoS One. 2011;6(10):e25446
pubmed: 22022397
Alzheimers Dement. 2016 Mar;12(3):292-323
pubmed: 27012484
Neurology. 2011 Apr 19;76(16):1395-402
pubmed: 21490323
Dementia (London). 2018 Nov;17(8):1045-1054
pubmed: 30373458
Neurology. 2002 Apr 23;58(8):1188-96
pubmed: 11971085
Hum Brain Mapp. 2009 Oct;30(10):3238-53
pubmed: 19277975
Cereb Cortex. 2010 Sep;20(9):2069-79
pubmed: 20051356
Arch Neurol. 2009 Dec;66(12):1476-81
pubmed: 20008651
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
Neurobiol Aging. 2001 Sep-Oct;22(5):747-54
pubmed: 11705634
Alzheimers Res Ther. 2018 Sep 27;10(1):100
pubmed: 30261928
Ann Neurol. 2011 Jun;69(6):1032-42
pubmed: 21437929
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Neuroimage. 2008 Nov 15;43(3):458-69
pubmed: 18691658
J Alzheimers Dis. 2018;64(4):1099-1112
pubmed: 30010132
Semin Neurol. 2013 Sep;33(4):386-416
pubmed: 24234359
Nat Rev Neurol. 2010 Feb;6(2):67-77
pubmed: 20139996
Alzheimers Dement. 2011 May;7(3):257-62
pubmed: 21514247
Alzheimers Res Ther. 2018 Oct 30;10(1):112
pubmed: 30376881
Neuroimage. 2002 Jan;15(1):273-89
pubmed: 11771995
Ann Neurol. 2009 Apr;65(4):403-13
pubmed: 19296504
Neuroimage. 2017 Jul 15;155:530-548
pubmed: 28414186
J Alzheimers Dis. 2013;35(4):715-26
pubmed: 23481686
Neuroimage. 2006 Jun;31(2):627-40
pubmed: 16480900
J Alzheimers Dis. 2014;41(3):685-708
pubmed: 24718104
Neuroimage Clin. 2018 Apr 16;19:190-201
pubmed: 30023169
Neuroimage. 2010 Mar;50(1):162-74
pubmed: 19961938
PLoS One. 2011;6(7):e22193
pubmed: 21829449
Alzheimers Dement (N Y). 2016 Mar 03;2(2):82-92
pubmed: 29067295
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Bioinformatics. 2007 Oct 1;23(19):2507-17
pubmed: 17720704
JAMA. 2015 May 19;313(19):1924-38
pubmed: 25988462